Lantus Follow-On Basaglar OK'd, But Can Lilly Sell It?
This article was originally published in Scrip
Eli Lilly & Co. and its partner Boehringer Ingelheim GmbH won the first-ever US approval of a follow-on version of Sanofi SA's Lantus (insulin glargine) – a clearance for marketing that was permitted under the FDA's 505(b)(2) abbreviated pathway, which permits an application to rely, in part, on safety and efficacy data from an innovator's product.
You may also be interested in...
Mylan is the first to launch insulin glargine competition in both a vial and pre-filled pen, joining Eli Lilly's Basaglar pen.
Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.
The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.